Good to see revenue headed in the right direction hopefully gains will be exponential from here. Looks like MA will take longer for EVIO than would be ideal considering the huge demand, same could be said for Canada if I am reading correctly. From the CEO notes it seems there is good progress on several fronts though. Would appreciate if anyone has any insight on competition (for instance who is doing the testing in MA while EVIO gets their stuff in order). Let’s hope we are at the end of dilution and share price will increase in accordance with revenue. I’d also like to see some more (positive) analyst coverage I mean it’s not like cannabis is an under covered space right now. I’m also curious if management is buying shares at recent prices. I continue to hold and hope the now increasing revenue will drive out some shorts. Happy thanksgiving everyone.